Realm Therapeutics names Ivan Gergel as non-executive director
Dr. Gergel is currently Senior Vice President Drug Development and Chief Medical Officer at Nektar Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco.
Prior to Nektar Therapeutics, Dr. Gergel held various positions in the biopharmaceutical industry.
Dr. Gergel was Executive Vice President R&D and Chief Scientific Officer at Endo Pharmaceuticals and a Senior Vice President R&D at Forest Laboratories (subsequently acquired by Actavis/Allergan) and has advanced multiple compounds from research through approval.
Dr. Gergel began his career as a practicing psychiatrist before moving to SmithKline Beecham Pharmaceuticals where he held several roles, including Group Director, CNS in the US.
He has been a Board member of Corium International since 2014.
His prior Committee memberships include PhRMA Foundation, Pennsylvania Bio and USA-India Chamber of Commerce Scientific Advisory Board.
Dr. Gergel received his MBA from the Wharton School at the University of Pennsylvania. ■
LATEST MOVES FROM Pennsylvania
- Lannett Company appoints Patrick G. LePore to board
- Norwood Financial and Wayne Bank adds Meg L. Hungerford to board
- MSA Safety appoints Nishan J. Vartanian as COO
- Recro Pharma appoints Ryan D. Lake as SVP, finance
- Knoll CFO Craig Spray to resign
More inside POST